fb_script

JDRF clinical research features at American Diabetes Association’s (ADA) Scientific Sessions 2018

This year’s American Diabetes Association’s (ADA) Scientific Sessions in Orlando, Florida highlighted some important JDRF-supported research underway, encompassing breakthrough clinical trials and significant research findings that are paving the way to novel and emerging treatments for T1D.

Read More

First class of future research leaders feel fibre might find a faster cure

A world first program designed to help medical researchers in type one diabetes develop their leadership skills to help take innovations out of the lab and into the real world has graduated its first intake. The graduates, announced in Canberra on June 26th 2018, have already put their skills into practice, securing funding to look at a dietary supplement that could stop type one diabetes. Read More

Insulin pump with predictive low glucose management function reduces hypoglycaemia exposure in young people with type 1 diabetes

A T1DCRN funded clinical trial published in Diabetes Care has shown that a pump with the ability to suspend insulin delivery when blood glucose levels begin to fall can reduce hypoglycaemic episodes without deterioration in glycaemic control.

Members of the PLGM study team L-R: Dr Mary Abraham, Prof Tim Jones, Dr Charles Czank, Prof Liz Davis and Ms Jennifer Nicholas

The integration of real-time continuous glucose monitoring systems and pump therapy has been an important milestone in the management of type 1 diabetes, and advances in the technology field offers the potential to further improve clinical outcomes.

Read More

Results from the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT)

The international AdDIT trial group have this month published results of a four year clinical trial in The New England Journal of Medicine, finding that ACE inhibitors and statins did not change the primary outcome – the albumin to creatinine ratio – compared to placebo in adolescents with type 1 diabetes (T1D).  Read More

The shape of the glucose concentration curve during an OGTT predicts risk for T1D

A recent study published in Diabetologia from the TrialNet group has found that the shape of the glucose curve during a glucose tolerance test predicted risk of type 1 diabetes (T1D) development. TrialNet is an international network of leading academic institutions, clinicians, scientists and healthcare teams dedicated to the prevention of T1D. Read More

Immunotherapy found to be safe in pilot study of people with T1D

A pilot clinical trial in the US has found a new immunotherapy treatment to be safe in people with new onset type 1 diabetes (T1D).

After clinical presentation of T1D, beta cell loss continues progressively in most people until C-peptide levels, a marker of endogenous insulin production, is absent or present in very low levels. Despite intensive research efforts for more than 20 years, no therapy is currently available to prevent beta cell loss in T1D.

Read More

Importance of coeliac disease screening in people with T1D

A large multinational study including data from 52,721 participants have found international differences in prevalence of coeliac disease (CD) in those with T1D. Coeliac disease has a known association with T1D, and this study aimed to examine global differences in prevalence and management to improve understanding of the impact of both conditions.

Read More

Findings may improve prediction of T1D risk for prevention studies

TrialNet is an international collaborative network that aims to prevent, delay and reverse the progression of type 1 diabetes, involving United States, Canada, Finland, United Kingdom, Italy, Germany, Australia and New Zealand.

TrialNet in Australia/New Zealand is led by A/Prof John Wentworth at Walter & Eliza Hall Institute (WEHI) in collaboration with Prof Peter Colman AM.

Read More

T1DCRN awards $350K in seed funding grants

Two promising research projects have been targeted to receive contract seed funding grants, and will benefit from $350K in funding from the Type 1 Diabetes Clinical Research Network (T1DCRN), itself an innovative clinical research program led by JDRF Australia and funded by a Special Research Initiative through the Australian Research Council (ARC).

Professor Peter Thorn (left) and Dr Vincent Ho

These two projects will explore new directions in curing and treating T1D and its complications. Read More

Tool could help predict lack of ‘honeymoon phase’ in young people with type 1 diabetes

A new study has developed a prediction tool to help clinicians predict which newly diagnosed children and adolescents are unlikely to experience a period of remission.

The remission phase, also called the honeymoon phase, is the period of time after clinical diagnosis of T1D where the body can make just enough insulin (“endogenous” insulin) to control blood glucose levels either without needing insulin injections or with significantly lower doses.  Read More